Related references
Note: Only part of the references are listed.Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV
Yves Levy et al.
AIDS (2012)
Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation
Fanny Guimont-Desrochers et al.
BLOOD (2012)
Exploiting antitumor immunity to overcome relapse and improve remission duration
Lei L. Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Sophie Viaud et al.
CANCER RESEARCH (2011)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG
J. Henry Evans et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
David Saadoun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
Cedric Menard et al.
CANCER RESEARCH (2009)
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth
Robbert G. van der Most et al.
PLOS ONE (2009)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2
Gregoire Mignot et al.
JOURNAL OF IMMUNOLOGY (2008)
Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
Nicolas Larmonier et al.
JOURNAL OF IMMUNOLOGY (2008)
Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions
Evelyn Ullrich et al.
JOURNAL OF IMMUNOLOGY (2008)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Interferon-producing killer dendritic ceRs (IKDCs) arise via a unique differentiation pathway from primitive c-kit(Hi)CD62L(+) lymphoid progenitors
Robert S. Welner et al.
BLOOD (2007)
A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer
Manisha H. Shah et al.
CLINICAL CANCER RESEARCH (2006)
Chemoimmunotherapy of tumors:: Cyclophosphamide synergizes with exosome based vaccines
Julien Taieb et al.
JOURNAL OF IMMUNOLOGY (2006)
A novel dendritic cell subset involved in tumor immunosurveillance
J Taieb et al.
NATURE MEDICINE (2006)
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity
CW Chan et al.
NATURE MEDICINE (2006)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients
JA Kovacs et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients
I Sereti et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics
G Marchetti et al.
AIDS (2004)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
